The aim of this study was to assess the safety and effectiveness of > or =4 sirolimus-eluting stent (SES; Cypher, Cordis, Johnson and Johnson) implantation. The safety of implantation of > or =4 SESs in the same patient and setting has not been established. Furthermore, it has been hypothesized that sirolimus administration with the use of multiple stents may diminish the platelet inhibitory effects of clopidogrel and may trigger drug-drug interactions. We identified 96 consecutive patients (96 procedures) who underwent implantation of > or =4 SESs in 365 lesions (438 stents) during the same procedure. All patients received aspirin indefinitely and clopidogrel or ticlopidine for at least 1 year postprocedure; 57% and 47% of the patients were on calcium channel blocker and statin therapy, respectively. All stents were successfully deployed and glycoprotein IIb/IIIa inhibitors were used in 50% of the procedures. There were no in-hospital deaths, Q-wave myocardial infarction (MI), urgent bypass surgery, or repeat percutaneous coronary intervention; 18 patients (19%) suffered non-Q-wave MI (defined as CK-MB elevation >3 times the upper limit of normal). At 30-day follow-up, there was one (1%) subacute thrombosis resulting in target lesion revascularization. At mean follow-up time of 15.4 +/- 6.2 months, the frequency of target lesion revascularization, target vessel revascularization, and major adverse cardiac event rates were 12%, 16%, and 18%, respectively. No other notable clinical events that might have been attributed to the possible drug-drug interactions or discontinuation of concomitant antithrombotic, statin, or calcium channel blocker therapy were reported. Multiple (> or =4) SES implantation appears safe with no increase in major adverse cardiac events.

Iakovou, I., Sangiorgi, G., Stankovic, G., Corvaja, N., Vitrella, G., Ferraro, P.m., et al. (2005). Results and follow-up after implantation of four or more sirolimus-eluting stents in the same patient. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 64(4), 436-436-9; discussion 440-1 [10.1002/ccd.20305].

Results and follow-up after implantation of four or more sirolimus-eluting stents in the same patient

SANGIORGI, GIUSEPPE;FERRARO, PIETRO MANUEL;
2005-04-01

Abstract

The aim of this study was to assess the safety and effectiveness of > or =4 sirolimus-eluting stent (SES; Cypher, Cordis, Johnson and Johnson) implantation. The safety of implantation of > or =4 SESs in the same patient and setting has not been established. Furthermore, it has been hypothesized that sirolimus administration with the use of multiple stents may diminish the platelet inhibitory effects of clopidogrel and may trigger drug-drug interactions. We identified 96 consecutive patients (96 procedures) who underwent implantation of > or =4 SESs in 365 lesions (438 stents) during the same procedure. All patients received aspirin indefinitely and clopidogrel or ticlopidine for at least 1 year postprocedure; 57% and 47% of the patients were on calcium channel blocker and statin therapy, respectively. All stents were successfully deployed and glycoprotein IIb/IIIa inhibitors were used in 50% of the procedures. There were no in-hospital deaths, Q-wave myocardial infarction (MI), urgent bypass surgery, or repeat percutaneous coronary intervention; 18 patients (19%) suffered non-Q-wave MI (defined as CK-MB elevation >3 times the upper limit of normal). At 30-day follow-up, there was one (1%) subacute thrombosis resulting in target lesion revascularization. At mean follow-up time of 15.4 +/- 6.2 months, the frequency of target lesion revascularization, target vessel revascularization, and major adverse cardiac event rates were 12%, 16%, and 18%, respectively. No other notable clinical events that might have been attributed to the possible drug-drug interactions or discontinuation of concomitant antithrombotic, statin, or calcium channel blocker therapy were reported. Multiple (> or =4) SES implantation appears safe with no increase in major adverse cardiac events.
apr-2005
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/11 - Malattie dell'Apparato Cardiovascolare
English
Con Impact Factor ISI
Sirolimus; Severity of Illness Index; Drug Delivery Systems; Coronary Angiography; Humans; Retrospective Studies; Aged; Coronary Restenosis; Coronary Stenosis; Angioplasty, Balloon, Coronary; Risk Assessment; Vascular Patency; Survival Rate; Cohort Studies; Treatment Outcome; Stents; Follow-Up Studies; Middle Aged; Time Factors; Female; Male
Iakovou, I., Sangiorgi, G., Stankovic, G., Corvaja, N., Vitrella, G., Ferraro, P.m., et al. (2005). Results and follow-up after implantation of four or more sirolimus-eluting stents in the same patient. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 64(4), 436-436-9; discussion 440-1 [10.1002/ccd.20305].
Iakovou, I; Sangiorgi, G; Stankovic, G; Corvaja, N; Vitrella, G; Ferraro, Pm; Colombo, A
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/108609
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 2
social impact